We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Point-of-Care CD4 Counter Evaluated

By LabMedica International staff writers
Posted on 10 Jan 2013
The measurement of the absolute CD4 T-cell count is critical in the initial evaluation and staging of persons infected human immunodeficiency virus (HIV). More...


However, access to the technology that allows for such measurements remains limited in many low resource settings where disease burden of HIV and acquired immunodeficiency disease syndrome (AIDS) is highest.

Scientists at MBio Diagnostics (Boulder, CO, USA) working with colleagues at the University of California (San Diego, CA, USA) evaluated the performance of a prototype point-of-care device (POC) to quantify CD4 T cells. The device combines single-use, disposable cartridges with a simple reader instrument. Based on the principle of static imaging cytometry with fluorescent immunostaining, the system utilizes a novel, laser-based illumination approach combined with MBio's proprietary planar waveguide technology.

A total of 94 participants provided venous whole blood samples and 52 capillary whole blood specimens. Study participants were HIV-infected individuals enrolled through a large primary HIV care program, at the University of California, San Diego between May 2011 and October 2011. Participants were predominantly male, of Caucasian and Hispanic race/ethnicity, with a median age of 44 years. The device, known as the Snapcount system, is a product of MBio Diagnostics and was compared with conventional flow cytometry (FACSCalibur, Becton Dickinson).

The prototype MBio system showed negligible quantitative bias relative to flow cytometry. Higher variability was observed in the capillary samples relative to venipuncture, but system precision was good for both capillary and venipuncture samples. There was also close agreement between results from the same participant when tested with two different systems, different operators, and different locations.

The authors wrote that developmental efforts are underway on a cartridge that incorporate lyophilized reagents and allows direct whole blood addition combined with a reader device. The reader device would include an integrated touch screen, internal and external quality control features, and data management software and network connectivity. The study was published in the January 2013 edition of the Journal of Immunological Methods.


Related Links:
MBio Diagnostics
University of California San Diego
Becton Dickinson


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.